ImmunoSensation - the immune sensory system

Eur J Haematol. 2020 Feb 12.

Long-term follow-up of Cladribine, high-dose Cytarabine and Idarubicin as salvage treatment for Relapsed acute myeloid Leukemia and Literature Review.

Mayer K, Hahn-Ast C, Schwab K, Schmidt-Wolf IGH, Brossart P, Glasmacher A, von Lilienfeld-Toal M

Outcome for relapsed acute myeloid leukemia (AML) is poor. Cladribine has activity in AML and an enhancing effect on other cytostatic drugs thus may help overcome resistance. Here, we present the final analysis of our phase II trial evaluating safety and efficacy of cladribine, cytarabine and idarubicin (CAI) in relapsed AML.

PMID: 32049382